Please use this identifier to cite or link to this item:
http://hdl.handle.net/1843/70586
Type: | Artigo de Periódico |
Title: | Novel symmetrical 1,4-Disubstituted-bis-1,2,3-Triazoles: synthesis by double CuAAC and cytotoxicity evaluation |
Authors: | Wallace Junio Reis Paulo Otávio Lourenço Moreira Rosemeire Brondi Alves Heloísa Helena Marques Oliveira Luciana M. Silva Fernando de Pilla Varotti Rossimiriam Pereira de Freitas |
Abstract: | Background: A series of symmetrical 1,4-disubstituted bis-1,2,3-triazoles was prepared by double copper catalyzed Azide-alkyne Cycloaddition (CuAAC) from aliphatic bis-azides and a tetraethylene glycol bis-azide derivative. The eighteen novel compounds were evaluated in vitro for their cytotoxic activity against two human tumor cell lines: Human breast adenocarcinoma (MDA-MB 231) and ovarian adenocarcinoma (TOV-21G). Results and Conclusion: The results of colorimetric MTT assays showed that compounds 4j and 4q exhibited a better selectivity index and cell viability comparable with the standard drug doxorubicin. These compounds induced apoptosis in both tested cell lines, as assessed by BrdU assay. The results suggest that these structurally simple compounds may be promising prototypes for antitumoral agents. |
Subject: | Triazóis Apoptose Citotoxidade de mediação celular Agentes antineoplásicos Química farmacêutica |
language: | eng |
metadata.dc.publisher.country: | Brasil |
Publisher: | Universidade Federal de Minas Gerais |
Publisher Initials: | UFMG |
metadata.dc.publisher.department: | ICX - DEPARTAMENTO DE QUÍMICA |
Rights: | Acesso Restrito |
metadata.dc.identifier.doi: | http://dx.doi.org/10.2174/1568026618666181022124847 |
URI: | http://hdl.handle.net/1843/70586 |
Issue Date: | 2018 |
metadata.dc.url.externa: | https://www.eurekaselect.com/article/93875 |
metadata.dc.relation.ispartof: | Current Topics in Medicinal Chemistry |
Appears in Collections: | Artigo de Periódico |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.